Article info
PDFReview
Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions
- Correspondence to Dr Giuseppe Caruso, Department of Maternal and Child Health and Urological Sciences, University of Rome La Sapienza, Rome, Lazio, Italy; g.caruso{at}uniroma1.it
Citation
Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions
Publication history
- Received November 16, 2022
- Accepted February 9, 2023
- First published March 16, 2023.
Online issue publication
April 03, 2023
Article Versions
- Previous version (16 March 2023).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.